Clinical Trials Logo

Hematologic Malignancy clinical trials

View clinical trials related to Hematologic Malignancy.

Filter by:
  • Enrolling by invitation  
  • Page 1

NCT ID: NCT06208878 Enrolling by invitation - Clinical trials for Hematologic Malignancy

A Long-term Follow-up Study of Subjects Who Received CRISPR CAR T Cellular Therapies

Start date: November 22, 2023
Phase:
Study type: Observational

This study will evaluate the long-term safety and efficacy of CRISPR CAR T cellular therapies

NCT ID: NCT05889806 Enrolling by invitation - Clinical trials for Cardiovascular Diseases

AUD Biomarkers Study (Proteomic and Genomic Analysis of Biospecimens)

Start date: May 10, 2023
Phase:
Study type: Observational

Study purpose: to explore the entire spectrum of proteomic and genomic changes (amongst others) involved in diseases and in healthy/control populations. The Study is designed to discover biomarkers, develop and validate diagnostic assays, instruments and therapeutics as well as other medical research. Specifically, researchers may analyze proteins, RNA, DNA copy number changes, including large and small (1,000-100,000 kb) scale rearrangements, transcription profiles, epigenetic modifications, sequence variation, and sequence in both diseased tissue and case-matched germline DNA from Subjects.

NCT ID: NCT05600933 Enrolling by invitation - Lung Cancer Clinical Trials

Prospective Procurement of Tumor Tissue to Identify Novel Therapeutic Targets and Study the Tumor Microenvironment

Start date: May 15, 2023
Phase:
Study type: Observational

Background: Many advances have been made in cancer treatments, but more research is needed. Comparing samples of cancerous tissue to samples of normal, noncancerous tissues may help find differences between them. These differences may help researchers find new ways to treat cancer. Objective: To collect tissues and blood samples from people with known or suspected cancer. The samples will be used to help identify new targets for cancer treatments. Eligibility: People aged 18 years and older with a known or suspected cancer that requires surgery or biopsy. Design: Participants will be screened. They will answer questions about their health. They can do this on the phone or in person. Researchers will collect information from participants medical records. Data may include information about any prior or current cancers. Data about other medical conditions may also be collected. Participants will have blood drawn. Some of the blood will be tested for HIV and hepatitis B and C. Some of the blood will be used for genetic research. Participants will have tissue samples collected during surgeries or biopsies. These are procedures the participants would have had as part of their standard care. No new procedures will be done just for this study. Researchers may also seek out samples from prior procedures the participant had done. Participants will remain in the study for 6 months. They may have blood drawn again. Researchers may also collect tissue samples from any procedures performed during that time.

NCT ID: NCT05332054 Enrolling by invitation - Lymphoma Clinical Trials

Long-Term Follow-up Study

LTFS
Start date: March 16, 2022
Phase:
Study type: Observational

This is a non-interventional, long-term safety study of allogeneic CAR-T cell therapy in patients who have participated in a prior Caribou-sponsored clinical study, in a special access program, or in another study such as an IIT. Its purpose of is to collect long-term observational data to identify and understand potential late side effects in patients who have received CAR-T cell therapies.

NCT ID: NCT05038722 Enrolling by invitation - Thrombocytopenia Clinical Trials

Function of Platelets Used for Transfusions

Start date: November 22, 2018
Phase:
Study type: Observational

Cytotoxic treatment for malignant hematologic disorders often casue thrombocytopenia that can result in life threatening bleedings. This is prevented by platelet transfusions but these can cause serious transfusion reactions and thus the number of transused platelet concentrates should be limited. It is therefore important that the platelet concentrates contain functional platelets with long circulation time in the bloodstream. We have developed a method with flow cytometry to measure platelet function markers. It allows us to determine which pathways that are initiated upon activation. The aim of this project is to assess to what degree spontaneous activation of platelets as well as their activation capacity affects the transfusion response (i.e. uptake in the circulation and circulation time) in the recipient. The hypothesis is that transfusion of platelets with low spontaneous activation and high activation capacity will lead to a higher transfusion response in the recipient.